# Myokine Levels in Relation to Bone Markers and Adipokines in Children with Prader–Willi Syndrome During Growth Hormone Therapy and Dietary Intervention

**Authors:** Joanna Gajewska, Magdalena Chełchowska, Katarzyna Szamotulska, Małgorzata Strucińska, Witold Klemarczyk, Jadwiga Ambroszkiewicz

PMC · DOI: 10.3390/ijms262210822 · International Journal of Molecular Sciences · 2025-11-07

## TL;DR

This study examines how muscle, bone, and fat metabolism interact in children with Prader-Willi syndrome during growth hormone therapy and diet changes.

## Contribution

The study identifies altered myokine, osteokine, and adipokine profiles in children with Prader-Willi syndrome.

## Key findings

- Children with Prader-Willi syndrome had lower irisin and osteocalcin levels compared to controls.
- Irisin positively correlated with bone alkaline phosphatase and negatively with Gla-OC and periostin in PWS children.
- Myostatin was negatively associated with lean mass and positively with proinsulin in PWS patients.

## Abstract

Data on the interplay between muscle, bone, and adipose tissue metabolism in normal-weight children with Prader–Willi syndrome (PWS) undergoing growth hormone (GH) therapy and dietary interventions are limited. This study aimed to assess the myokine profile and explore the associations between myokines, bone markers, adipokines, and body composition in these patients. The study included 26 children with PWS and 26 age-matched healthy controls. Serum levels of irisin, myostatin (MSTN), fibroblast growth factor-2, insulin-like growth factor-I (IGF-I), IGF-binding protein-2, bone alkaline phosphatase (BALP), osteocalcin (OC), carboxylated OC (Gla-OC), periostin, soluble receptor activator of nuclear factor kappa-B ligand, tartrate-resistant acid phosphatase 5b, leptin/soluble leptin receptor, adiponectin, and proinsulin were measured using immunoenzymatic assays. Children with PWS had significantly lower lean mass (p = 0.047) and a higher fat mass/lean mass ratio (p < 0.001) than controls. Irisin levels were lower in the PWS group (p = 0.031), while MSTN levels were similar between the groups. In patients, irisin positively correlated with BALP (p = 0.025) and negatively correlated with Gla-OC (p = 0.041) and periostin (p = 0.005). MSTN was positively associated with proinsulin (p = 0.001) and negatively associated with lean mass (p = 0.015). OC concentration was lower in the PWS group and correlated positively with lean mass (p = 0.052). Children with PWS exhibit altered myokine, osteokine, and adipokine profiles, as well as differences in body composition. Reduced irisin and osteocalcin levels, along with the negative association between MSTN and lean mass, may impair muscle development and bone metabolism. These imbalances could also contribute to future metabolic disorders in patients with PWS.

## Linked entities

- **Proteins:** LOC5521725 (growth/differentiation factor 8), FNDC5 (fibronectin type III domain containing 5), bglap2 (bone gamma-carboxyglutamate (gla) protein (osteocalcin) 2), postn (periostin, osteoblast specific factor), lepa (leptin a), INS (insulin)
- **Diseases:** Prader-Willi syndrome (MONDO:0008300)

## Full-text entities

- **Genes:** FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, FNDC5 (fibronectin type III domain containing 5) [NCBI Gene 252995] {aka FRCP2, irisin}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}, POSTN (periostin) [NCBI Gene 10631] {aka OSF-2, OSF2, PDLPOSTN, PN}, IGFBP2 (insulin like growth factor binding protein 2) [NCBI Gene 3485] {aka IBP2, IGF-BP53}, LEPR (leptin receptor) [NCBI Gene 3953] {aka CD295, LEP-R, LEPRD, OB-R, OBR, huB219}, BGLAP (bone gamma-carboxyglutamate protein) [NCBI Gene 632] {aka BGP, OC, OCN}, ADIPOQ (adiponectin, C1Q and collagen domain containing) [NCBI Gene 9370] {aka ACDC, ACRP30, ADIPQTL1, ADPN, APM-1, APM1}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, ACP5 (acid phosphatase 5, tartrate resistant) [NCBI Gene 54] {aka HPAP, TRACP5a, TRACP5b, TRAP, TRAcP, TrATPase}
- **Diseases:** PWS (MESH:D011218), metabolic disorders (MESH:D008659)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12652224/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12652224/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC12652224/full.md

---
Source: https://tomesphere.com/paper/PMC12652224